References
- T. M. Allen. (1994). Long-circulating (sterically stabilized) liposomes for targeted drug delivery. Trends Pharmacol Sci 15:215–220.
- T. M. Allen. (1997). Liposomes. Opportunities in drug delivery. Drugs 54 (Suppl 4):8–14.
- L. Cattel, M. Ceruti, and F. Dosio. (2003). From conventional to stealth liposomes: a new frontier in cancer chemotherapy. Tumori 89:237–249.
- A. Gabizon, and F. Martin. (1997). Polyethylene glycol-coated (pegylated) liposomal doxorubicin. Rationale for use in solid tumours. Drugs 54 (Suppl 4):15–21.
- C. M. Gupta, and A. Bali. (1981). Biochim Biophys Acta 663:506–515.
- M. Hussein. (2003). Pegylated liposomal doxorubicin, vincristine, and reduced-dose dexamethasone as first-line therapy for multiple myeloma. Clin Lymphoma 4 (Suppl 1):S18–S22.
- D. Needham, G. Anyarambhatla, G. Kong, and M. W. Dewhirst. (2000). A new temperature-sensitive liposome for use with mild hyperthermia: characterization and testing in a human tumor xenograft model. Cancer Res 60:1197–1201.
- D. Needham, and M. W. Dewhirst. (2001). The development and testing of a new temperature-sensitive drug delivery system for the treatment of solid tumors. Adv Drug Deliv Rev 53:285–305.
- D. F. Nellis, D. L. Ekstrom, D. B. Kirpotin, J. Zhu, R. Andersson, T. L. Broadt, T. F. Ouellette, S. C. Perkins, J. M. Roach, D. C. Drummond, K. Hong, J. D. Marks, J. W. Park, and S. L. Giardina. (2005). Preclinical manufacture of an anti-HER2 scFv-PEG-DSPE, liposome-inserting conjugate. 1. Gram-scale production and purification. Biotechnol Prog 21:205–220.
- D. F. Nellis, S. L. Giardina, G. M. Janini, S. R. Shenoy, J. D. Marks, R. Tsai, D. C. Drummond, K. Hong, J. W. Park, T. F. Ouellette, S. C. Perkins, and D. B. Kirpotin. (2005). Preclinical manufacture of anti-HER2 liposome-inserting, scFv-PEG-lipid conjugate. 2. Conjugate micelle identity, purity, stability, and potency analysis. Biotechnol Prog 21:221–232.
- C. O. Noble, D. B. Kirpotin, M. E. Hayes, C. Mamot, K. Hong, J. W. Park, C. C. Benz, J. D. Marks, and D. C. Drummond. (2004). Development of ligand-targeted liposomes for cancer therapy. Expert Opin Ther Targets 8:335–353.
- A. Orlova, V. Tolmachev, R. Pehrson, M. Lindborg, T. Tran, M. Sandstrom, F. Y. Nilsson, A. Wennborg, L. Abrahmsen, and J. Feldwisch. (2007). Synthetic affibody molecules: a novel class of affinity ligands for molecular imaging of HER2-expressing malignant tumors. Cancer Res 67:2178–2186.
- J. W. Park. (2002). Liposome-based drug delivery in breast cancer treatment. Breast Cancer Res 4:95–99.
- J. W. Park, C. C. Benz, and F. J. Martin. (2004). Future directions of liposome- and immunoliposome-based cancer therapeutics. Semin Oncol 31:196–205.
- J. W. Park, K. Hong, D. B. Kirpotin, G. Colbern, R. Shalaby, J. Baselga, Y. Shao, U. B. Nielsen, J. D. Marks, D. Moore, D. Papahadjopoulos, and C. C. Benz. (2002). Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery. Clin Cancer Res 8:1172–1181.
- A. M. Ponce, Z. Vujaskovic, F. Yuan, D. Needham, and M. W. Dewhirst. (2006). Hyperthermia mediated liposomal drug delivery. Int J Hyperthermia 22:205–213.
- P. Sapra, P. Tyagi, and T. M. Allen. (2005). Ligand-targeted liposomes for cancer treatment. Curr Drug Deliv 2:369–381.
- V. P. Torchilin. (1985). Liposomes as targetable drug carriers. Crit Rev Ther Drug Carrier Syst 2:65–115.
- V. P. Torchilin. (2005). Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov 4:145–160.
- J. N. Weinstein, R. L. Magin, D. S. Zaharko, M. B. Yatvin, and R. Blumenthal. (1979). Use of Hyperthermia for Selective Localization of Liposomal Methotrexate in Tumors. Biophysical Journal 25:A291.
- M. B. Yatvin, J. N. Weinstein, W. H. Dennis, and R. Blumenthal. (1978). Design of liposomes for enhanced local release of drugs by hyperthermia. Science 202:1290–1293.